The Pharma Data

NOVEMBER 11, 2020

TOKYO & AUSTIN, Texas–( BUSINESS WIRE )– Taiho Pharmaceutical Co., Lung Tx”) announced today an exclusive license agreement of LTI-01 , a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions , for the territory of Japan.

Licensing 40

Licensing Licensing Treatment Pharma Companies 40

DrugBank

MARCH 22, 2024

Due to open source data’s accessibility, it is an appealing resource for drug research as it often enables cost-effective sources for emerging pharmaceutical companies and academic research projects.  Paid Knowledge Bases Paying for access or licensing a knowledge base can be a difficult decision to make.

Licensing 98

Licensing Licensing Research Clinical Trials 98

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

OCTOBER 21, 2020

Under an exclusive licensing agreement with Endo International’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, Par Pharmaceuticals’ Sterile Products division will launch and distribute the product. and Canada. and Canada. Founder, Chairman and Chief Executive Officer of Nevakar. . Nevakar Inc.

FDA Approval 40

FDA Approval FDA Pharmaceutical Companies Pharmaceuticals 40

The Pharma Data

FEBRUARY 22, 2021

Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox’s trade secrets and grant a license to Evolus to continue to commercialize Jeuveau® in the United States and Nuceiva in all other territories in which Evolus has licensing rights.

Licensing 40

Licensing Licensing Pharmaceutical Companies Pharmaceuticals 40

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct.

Licensing 40

Licensing Licensing Pharmaceutical Companies Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

“We look forward to accelerating the development of SPR206 in Asia and working closely with our partners at Spero Therapeutics to advance this novel product candidate for patients around the world with limited treatment options.” SHANGHAI , Jan. ” About SPR206. About Everest Medicines.

Clinical Trials 52

Clinical Trials Clinical Development Pharmacokinetics Pharmaceutical Companies 52

The Pharma Data

JANUARY 4, 2021

5, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. ” About the License Agreement.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

The Pharma Data

JANUARY 27, 2021

28, 2021 /PRNewswire/ — CASI Pharmaceuticals (Formerly Known As EntreMed, Inc.). The Company’s validated, proprietary F.I.R.S.T biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China , the United States , and throughout the world.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 25, 2021

At their option, the collaboration with the European affiliate of a global pharmaceutical company has expanded to three active pharmaceutical ingredients (“API”s). We are well positioned for a productive 2021.”

Licensing 52

Licensing Licensing Production Regulations 52

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases. Noema Pharma .

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

NOVEMBER 10, 2020

Furthermore, data show that the class of drug substances being developed within AlzeCure’s platform, so-called gamma-secretory modulators, selectively affect the production of toxic Abeta-amyloid, without affecting the cleavage of other substrates that potentially play an important role in normal physiological function. in the brain.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40

The Pharma Data

NOVEMBER 5, 2020

05, 2020 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended September 30, 2020 and provided a corporate update. About Collegium Pharmaceutical, Inc.

Pharmaceuticals 52

Pharmaceuticals Production Marketing Pharmaceutical Companies 52

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

Most have focused on patents specifically licensed to pharmaceutical companies from academic institutions, where the vast majority of basic biological research takes place in America, most of it supported by NIH. The term NME refers to molecules that are unique among regulated or approved drug products in their mode of activity.

Research 52

Research Science FDA Pharmaceutical Companies 52

Molecule Blog

MARCH 17, 2023

The process of transforming a therapeutic or technology from the research and development stage into a market-ready product or service is intricate and laden with obstacles. The university then licenses the IP to an existing pharmaceutical company or a biotech startup, which takes on Investigational New Drug (IND) enabling studies.

Engineering 52

Engineering Research Clinical Trials Government 52

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Trials Pharmaceutical Companies Clinical Pharmacology 40

The Pharma Data

NOVEMBER 25, 2020

. Vivera Pharmaceuticals, Inc., is an innovative, science-driven pharmaceutical company focused on novel therapies for a variety of indications. Vivera is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products. . Source link.

Pharmaceuticals 40

Pharmaceuticals Hospitals Pharmaceutical Companies Licensing 40

The Pharma Data

JANUARY 10, 2021

Sébastien Peltier, CEO of VALBIOTIS, and Jocelyn Pineau, CFO, are taking part in this key event for biotechnology and pharmaceutical companies. Its products are intended to be licensed to players in the health sector.

International 40

International Pharmaceutical Companies Disease Licensing 40

The Pharma Data

NOVEMBER 5, 2020

The Janssen Pharmaceutical Companies of Johnson & Johnson announced two Phase III trials, DISCOVER-1 and 2 demonstrated Tremfya (guselkumab) improved fatigue in adults with active psoriatic arthritis (PsA). There was a handful of positive clinical trial news reported today. Here’s a look. Janssen’s Tremfya.

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

The Pharma Data

DECEMBER 27, 2020

Tyvaso DPI, previously referred to as Treprostinil Technosphere ® , is an investigational drug-device combination product comprised of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler. United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation.

FDA 52

FDA Bioinformatics Disease Production 52

The Pharma Data

DECEMBER 29, 2020

NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ® plant cell-based protein expression system, and Chiesi Global Rare Diseases , a business unit of Chiesi Farmaceutici S.p.A.,

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. Do you search for similar products, and use existing IND criteria requirements against the latest manufacturing guidance docs? A: Working in a pharmaceutical company is the best way to learn this. A: This does not usually happen.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

OCTOBER 14, 2020

is a pharmaceutical company conducting business in more than 70 countries around the world. Established in 2017, iota is a start-up company focused on building a foundation for the future of bioelectronic medicine. iota holds exclusive licenses to technologies developed at leading U.S. About Astellas. Astellas Pharma Inc.

Disease 40

Disease Production Pharmaceuticals Clinical Trials 40

The Pharma Data

NOVEMBER 22, 2020

MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. The DARPin® platform is a fast and cost-effective drug discovery engine, producing drug candidates with optimized properties for development and very high production yields.

Trials 40

Trials Clinical Trials Licensing Licensing 40

The Pharma Data

OCTOBER 18, 2020

Crist brings more than twenty years of oncology sales experience in both launch-stage and late-stage companies, building commercial organizations and developing high performing sales force teams. AVEO is an oncology focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients.

Clinical Trials 40

Clinical Trials FDA Treatment Trials 40

The Pharma Data

JANUARY 24, 2021

More than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.

FDA 40

FDA Clinical Trials Trials Treatment 40

Drug Target Review

SEPTEMBER 19, 2024

She has extensive experience in executive management, drug development, regulatory affairs and licensing with major international pharmaceutical companies, including in the field of neurodegenerative diseases.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

NOVEMBER 15, 2020

a publicly traded biopharmaceutical company, from 2012 to December 2019, managing its international, legal, quality, intellectual property and compliance functions, after serving in other executive roles at Acorda starting in 2004. Before joining Acorda, Ms. Shah also serves on the boards of several civic organizations and initiatives.

Clinical Trials 40

Clinical Trials Trials Production Therapies 40

The Pharma Data

JANUARY 5, 2021

It increases the optionality to the Company’s value proposition, leverages our endocrine expertise and adds a late-stage pivotal trial-ready orphan disease product to the existing Phase 3 programs for abaloparatide and elacestrant,” said Radius Chief Executive Officer, Kelly Martin. Theresa Strong, Ph.D., ” Clinical Highlights.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

OCTOBER 27, 2020

“As our core business continues to perform well, we have a solid footing to enter 2021 with several key product launches including the potential INCREASE product label expansion for Tyvaso, the Remunity Pump for Remodulin, and the Implantable System for Remodulin,” said Martine Rothblatt , Ph.D., SILVER SPRING, Md.

FDA 40

FDA Production Licensing Licensing 40

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. UC Berkeley claimed Genentech's product infringed on their broader patent, leading to a legal battle over ownership and royalties.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Learn more about Otsuka Pharmaceutical Company on its global website at [link].

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Trademarks are owned by or licensed to Janssen and the ViiV Healthcare group of companies. CABENUVA offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression.

FDA Approval 52

FDA Approval Treatment RNA FDA 52

Codon

FEBRUARY 13, 2024

By 2004, over a dozen companies were working on developing phage products and therapies, in locations ranging from Baltimore to Bangalore, where ten years previously, there had been none. Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries.

Therapies 135

Therapies Virus DNA Clinical Trials 135

DrugBank

NOVEMBER 7, 2023

ASHP’s full suite of drug information has been integrated into and made available through DrugBank, bringing together both company’s offerings to provide streamlined access to a broader range of high quality products.

Pharmacy 105

Pharmacy Community Pharmacies Pharmaceutical Companies Packaging 105

The Pharma Data

NOVEMBER 8, 2020

As our first NDA approved drug, Sesquient validates our business model of efficient development of critical care hospital injectable products,” added John Sedor, Chairman, CEO and co-founder of Sedor. Concurrently, Sedor is in discussions on securing capital to retain North American rights and commercialize the product.

FDA Approval 52

FDA Approval FDA Long-Term Care Facilities Treatment 52

The Pharma Data

MARCH 4, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) and Ovid Therapeutics Inc. I would like to thank Ovid for their thoughtful and productive collaboration. About Takeda Pharmaceutical Company Limited. President of Research and Development at Takeda.

Treatment 52

Treatment Clinical Trials Pharmaceutical Companies Trials 52